Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)

SAN FRANCISCO and SUZHOU, China, April 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dis...

2024-04-16 08:00 785

TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation

* FDA Fast Track designation granted for TLX101-CDx for glioma (brain cancer) imaging * Collaboration agreement announced for joint development and commercialisation with UCSF * PharmaLogic announced as commercial manufacturing and pharmacy distribution partner MELBOURNE, Australia, April 1...

2024-04-16 06:42 692

【C.S】Cordyceps Sunshine has extended its market footprint in the world's largest traditional Chinese herbal medicine market with the introduction of their Cinnamomum product line.

TAIPEI, April 16, 2024 /PRNewswire/ -- Cordyceps Sunshine Group【C.S】Group, having recently achieved a successful U.S. IPO, hosted the '2024 China International Biomedical Innovation Development Conference and Chinese Rare Medicinal Herbs Cinnamomum Industry Transformation and Upgrade Conference' ...

2024-04-16 06:00 882

【C.S】Cordyceps Sunshine has extended its market footprint in the world's largest traditional Chinese herbal medicine market with the introduction of their Cinnamomum product line.

Pre-clinical result of LP-005, a novel bi-functional complement antibody-fusion protein was unveiled by LongBio at WCN2024

BUENOS AIRES, Argentina, April 15, 2024 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. (referred to as "LongBio"), a leading biotech company dedicated to developing innovative protein treatments for nephrology, allergy, respiratory, hematology, ophthalmology, and other autoimmune and rare dise...

2024-04-16 02:00 749

First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial

Plus, Actinogen receives approval of its application for a UK Innovation Passport as part of the Innovative Licensing and Access Pathway (ILAP) for Xanamem in the treatment of Alzheimer's disease Enrolment in XanaCIDD phase 2a trial of cognitive impairment and depression has surpassed 90% SYDNE...

2024-04-15 20:30 844

GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA

– Gilead Awards US$4 Million Globally (Excluding the United States) Through the Gilead ALL4LIVER Grant – – World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee – – South Korea's Association of Liver Patients and Survivors and the Taiwan re...

2024-04-15 13:06 988

Bloomage Demonstrates Global Quality Management Excellence through On-Site Audit by Japan's PMDA

TOKYO, April 15, 2024 /PRNewswire/ -- Bloomage recently successfully completed the on-site Good Manufacturing Practice (GMP) audit conducted byJapan's Pharmaceuticals and Medical Devices Agency (PMDA). As the official regulatory agency for pharmaceuticals inJapan, the PMDA holds significant resp...

2024-04-15 08:30 876

Bloomage Demonstrates Global Quality Management Excellence through On-Site Audit by Japan's PMDA

【2024 AACR Late Breaking Research】TransThera announces clinical data of tinengotinib to treat patients with advanced solid tumors harboring actionable FGFR1-3 alterations

NANJING, China and GAITHURSBURG, Md., April 12, 2024 /PRNewswire/ -- TransThera Sciences, a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, announced the poster presentation at the 2024 American Association for Cancer Research (AACR) to disc...

2024-04-12 21:00 1589

Don't Miss Out - Join the 7th IFPA Conference: Uncovering the Broad Spectrum of Psoriatic Disease

STOCKHOLM, April 11, 2024 /PRNewswire/ -- IFPA is delighted to announce the 7th IFPA Conference set to take place fromJune 27th to June 29th, 2024, in the picturesque city ofStockholm, Sweden. This year's conference promises to be a pivotal event for experts and stakeholders in the field of psori...

2024-04-11 16:00 1226

Don't Miss Out - Join the 7th IFPA Conference: Uncovering the Broad Spectrum of Psoriatic Disease

Nanoform Enters Exclusive Partnership with CBC to Bring Best-in-Class Nanomedicine Technology to Japan

HELSINKI, Finland, April 11, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform") today announced a strategic partnership whereby CBC Co., Ltd. ("CBC"), will utilize its extensive experience in the Japanese pharmaceutical industry to identify opportunities for Nanoform's cutting-edge nanomedici...

2024-04-11 15:38 1235

Nuevocor Strengthens Leadership Team with Appointment of John Lee as Chief Medical Officer

SINGAPORE and PHILADELPHIA, April 11, 2024 /PRNewswire/ -- Nuevocor, a pre-clinical stage biotechnology company dedicated to developing novel medicines to treat cardiomyopathies with aberrant mechanobiology, today announces the appointment ofDr. John Lee, MD, PhD, as its Chief Medical Office...

2024-04-11 14:59 1321

J INTS BIO, AACR 2024 - 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, showing Clinical Benefits in the Ongoing Phase 1 Study

SEOUL, South Korea, April 11, 2024 /PRNewswire/ -- J INTS BIO announced the results of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation EGFR-TKI for NSCLC treatment, at the 8th April poster session of the 2024 American Cancer Research Society (AACR) Annual Meeting held inSan Diego,...

2024-04-11 14:56 1007

J INTS BIO, AACR 2024 - 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, showing Clinical Benefits in the Ongoing Phase 1 Study

CSafe unveils cutting-edge innovations to meet cold chain customer needs

The company will launch three new technologies at the upcoming LogiPharma 2024 event MONROE, Ohio, April 10, 2024 /PRNewswire/ -- CSafe, a leading active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, announces it is launching three new technol...

2024-04-10 22:50 1729

ACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research

NEWARK, Del., April 10, 2024 /PRNewswire/ -- Starting in 2023, ACROBiosystems has been continuously rolling out a series of innovative organoid-related products. At a range of significant international events, including the 2024 International Organoid Summit, the Alzheimer's Research UK Conferenc...

2024-04-10 21:00 1167

3Shape Charts Sustainable Course with Release of Comprehensive Sustainability Report 2023

Highlighted in the company's latest report, 3Shape plans to inspire sustainability awareness in the dental industry through its new 5-year sustainability plan. COPENHAGEN, Denmark, April 10, 2024 /PRNewswire/ -- 3Shape, the global innovator in digital dentistry, is proud to unveil its 2023 Susta...

2024-04-10 18:29 1179

Tsingke Showcases Cutting-Edge Biologics Solutions at Biologics 2024

BEIJING and PARIS, April 10, 2024 /PRNewswire/ -- On March 15th, Biologics 2024 successfully concluded inLondon, with 650 pharmaceutical, biotechnology, and academic representatives and over 50 exhibitors engaging in high-level discussions on the latest innovations in biologics discovery and deve...

2024-04-10 14:19 861

Tsingke Showcases Cutting-Edge Biologics Solutions at Biologics 2024

ACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research

TOKYO, April 10, 2024 /PRNewswire/ -- Starting in 2023, ACROBiosystems has been launching a continuous stream of innovative organoid-related products. Displaying their advancements at key global forums including the 2024 International Organoid Summit, Alzheimer's Research UK Conference 2024, and ...

2024-04-10 14:05 1441

R&D Progress: Enrollment of Subjects in Phase III Clinical Trial for Inhaled Aerosol Drug in Children by Kexing Biopharm

SHENZHEN, China, April 10, 2024 /PRNewswire/ -- Recently, Kexing Biopharm (688136.SH) announced that the Phase III clinical trial of Human Interferon α1b Inhalation Solution developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., had completed the enrollment of first p...

2024-04-10 11:41 1733

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held fromMarch 29th toApril 1st, 2024, in Shenzhen, China. The TICSSO was initiated by Prof. Xinghua Pan (Southern Medical University), Prof. Fuchou Tang (Peking Un...

2024-04-09 23:14 1384

BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3

SHANGHAI, April 9, 2024 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC2027. BC2027, which is BioCity's second first-in-class antibody drug conjugate (...

2024-04-09 22:10 1080

12 3 4 5 ... 292